Animalcare Group PLC (GB:ANCR)
LSE:ANCR
Want to see GB:ANCR full AI Analyst Report?
Top Page
Animalcare
(LSE:ANCR)
Select Model
Select Model
Rating:70Outperform
Price Target:
365.00 p
▲(53.36% Upside)
Action:Upgraded
Date:05/10/26
The score is driven primarily by solid financial stability (low leverage, consistent positive free cash flow) and a strong upward technical trend. Offsetting this are volatile net profitability (notably the large 2024-to-2025 margin swing) and only moderate valuation support given a modest dividend yield.
Positive Factors
Conservative leverage
Animalcare's low and improving debt-to-equity (~0.13 in 2025) signifies a conservative capital structure. That durable balance-sheet strength reduces refinancing risk, supports investment or M&A optionality, and provides a buffer through industry cycles, aiding long-term stability.
Negative Factors
Net-margin volatility
A dramatic net-margin swing (very high in 2024 then collapsing in 2025) signals earnings volatility and potential one-offs or inconsistent cost alignment. Such volatility weakens earnings predictability, complicates long-term planning and reduces confidence in sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Animalcare's low and improving debt-to-equity (~0.13 in 2025) signifies a conservative capital structure. That durable balance-sheet strength reduces refinancing risk, supports investment or M&A optionality, and provides a buffer through industry cycles, aiding long-term stability.
Read all positive factors
Animalcare (ANCR) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£228.89M
Dividend Yield2.18%
Average Volume (3M)66.93K
Price to Earnings (P/E)32.3
Beta (1Y)0.59
Revenue Growth20.04%
EPS Growth-46.44%
CountryUK
Employees226
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.05
Shares Outstanding69,045,944
10 Day Avg. Volume79,363
30 Day Avg. Volume66,930
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)1.43
Price to Sales (P/S)1.84
P/FCF Ratio15.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)£93.90M
Animalcare Business Overview & Revenue Model
Company Description
Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets. It is also involved in th...
How the Company Makes Money
Animalcare makes money mainly by selling animal health products (primarily for companion animals) into veterinary and related channels. Key revenue streams include: (1) Product sales of prescription veterinary medicines and other veterinary produc...
Animalcare Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
78
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 81.07M | 89.11M | 74.23M | 74.35M | 71.62M | 74.02M |
| Gross Profit | 37.52M | 42.14M | 34.06M | 43.35M | 40.66M | 39.42M |
| EBITDA | 14.03M | 16.68M | 13.43M | 11.82M | 11.04M | 10.15M |
| Net Income | 2.98M | 5.08M | 32.22M | 1.20M | 1.97M | -77.00K |
Balance Sheet | ||||||
| Total Assets | 163.87M | 158.10M | 158.81M | 106.79M | 118.24M | 110.00M |
| Cash, Cash Equivalents and Short-Term Investments | 9.92M | 2.91M | 11.71M | 4.64M | 6.04M | 5.63M |
| Total Debt | 21.02M | 15.21M | 24.01M | 5.88M | 11.44M | 10.96M |
| Total Liabilities | 50.62M | 43.56M | 45.50M | 28.90M | 39.26M | 31.20M |
| Stockholders Equity | 113.25M | 114.54M | 113.31M | 77.89M | 78.99M | 78.80M |
Cash Flow | ||||||
| Free Cash Flow | 11.12M | 10.70M | 11.72M | 7.73M | 6.48M | 10.81M |
| Operating Cash Flow | 11.41M | 10.92M | 11.93M | 10.28M | 9.43M | 14.02M |
| Investing Cash Flow | -63.51M | -5.24M | -34.85M | -2.86M | -3.12M | -2.96M |
| Financing Cash Flow | 29.22M | -14.74M | 32.53M | -8.95M | -5.70M | -10.96M |
Animalcare Technical Analysis
Positive
238.00
Price Trends
287.59
Positive
276.48
Positive
261.93
Positive
Market Momentum
12.14
Positive
77.42
Negative
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANCR, the sentiment is Positive. The current price of 238 is below the 20-day moving average (MA) of 332.00, below the 50-day MA of 287.59, and below the 200-day MA of 261.93, indicating a neutral trend. The MACD of 12.14 indicates Positive momentum. The RSI at 77.42 is Negative, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ANCR.
Animalcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £66.07M | -44.80 | 3.55% | ― | 1.44% | 359.79% | |
70 Outperform | £228.89M | 32.32 | 2.63% | 2.18% | 20.04% | -46.44% | |
60 Neutral | £68.83M | 2.80 | 7.82% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £71.05M | -3.21 | 103.62% | ― | 49.81% | 52.94% |
* Healthcare Sector Average
GB:ANCR
Animalcare
331.50
81.66
32.68%
GB:EAH
Eco Animal Health
97.00
34.50
55.20%
GB:STX
Shield Therapeutics
6.65
4.20
171.43%
GB:VLG
Venture Life
56.50
5.50
10.78%
Animalcare Corporate Events
Business Operations and StrategyDividendsFinancial DisclosuresM&A Transactions
Animalcare posts strong 2025 growth as Randlab deal, R&D push and Charterhouse-backed bid reshape group
Positive
May 6, 2026
Animalcare, an international animal health business, reported 2025 revenue up 20% to £89.1m, driven largely by the acquisition and integration of Randlab and modest like-for-like growth across all product categories. Underlying EBITDA rose 52...
Business Operations and StrategyDelistings and Listing ChangesM&A Transactions
Charterhouse to Take Animalcare Private in £235m Recommended Deal
Positive
Apr 16, 2026
Animalcare Group has agreed to a recommended acquisition by CCP PAW 2 Limited, an indirect subsidiary of Charterhouse Capital Partners, via a UK scheme of arrangement. The deal offers shareholders 336 pence in cash per share, valuing the company a...
Business Operations and StrategyM&A Transactions
Animalcare sets 2030 growth ambitions at London capital markets event
Positive
Mar 4, 2026
Animalcare Group, the AIM-quoted animal health business, is hosting a Capital Markets Event in London to detail the three pillars of its growth strategy and how it plans to accelerate expansion in the near to medium term. The company highlights a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.